Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 1981;1:202-209

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fletcher, A.
Right arrow Articles by Witztum, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fletcher, A.
Right arrow Articles by Witztum, J.

Arteriosclerosis, Vol 1, 202-209, Copyright © 1981 by American Heart Association

ARTICLES

Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings

A Fletcher, N Alkjaersig, G Schonfeld and J Witztum

Fibrinogen catabolism was studied by plasma fibrinogen chromatography and other methods in 99 subjects with hyperlipoproteinemia Types IIa, IIb, and IV, and in 24 control subjects with normal blood lipid values. Subjects with either a history of thromboembolic vascular disease or clinical evidence of atherosclerosis were excluded. Type II subjects (i.e., the combined group of Type IIa and IIb subjects) showed an elevation of plasma high molecular weight fibrinogen complexes, which is indicative of enhanced fibrin formation. They also showed an elevation of fibrinogen-first-derivative, which is indicative of fibrinogenolysis and increased plasma euglobulin activity. Subjects with Type IV hyperlipoproteinemia showed similar findings to those of Type II except that high molecular weight fibrinogen complex concentration was normal. Subsequently, 36 patients received a fat- controlled, low cholesterol diet and were studied in a blind, random, crossover study of dietary vs clofibrate treatment. Although total cholesterol and triglyceride levels fell significantly during the treatment periods, chromatographic findings of abnormal plasma fibrinogen remained unchanged.




ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1981 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.